Conference Track

Early Breast Cancer: Chemotherapy and Targeted Agents

Source: CCO Independent Conference Coverage of the 2006 Annual San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

TAC Combination Chemotherapy Predictive of Benefit for Additional Cytotoxic Treatments in Patients With Operable or Locally Advanced Breast Cancer
Trastuzumab Duration Does Not Affect Safety Profile of Patients Receiving Subsequent Anthracycline Therapy Following Paclitaxel Plus Trastuzumab
Neoadjuvant Paclitaxel/Lapatinib Clinically Active in Newly Diagnosed Inflammatory Breast Cancer
E75 Vaccine May Prevent Recurrence of High-Risk Breast Cancer in Disease-Free Women
Trastuzumab and Nonanthracycline-Based Chemotherapy Effective and Minimally Cardiotoxic in Adjuvant Breast Cancer Treatment
Neoadjuvant Cisplatin Active and Safe in Triple-Negative Breast Cancer
Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab Shows Favorable Safety Profile
EBCTCG Overview: Small Improvements in Treatment Regimens Produce Large Cumulative Effects in Early Breast Cancer Patients
Dose-Dense Adjuvant Chemotherapy Safe, Efficacious, and Well-Tolerated in High-Risk Breast Cancer Patients
RFS With Adjuvant Doxorubicin/Cyclophosphamide Followed by Paclitaxel Chemotherapy Inferior to Epirubicin-Based Chemotherapy in Operable Breast Cancer
Meta-Analysis Highlights Efficacy of Anthracycline-Based AdjuvantTherapy in Patients With HER2+ Breast Cancer

Expert Analysis

Chemotherapy and Targeted Agents

Faculty:

Edith A. Perez, MD
Nicholas J. Robert, MD
Joseph A. Sparano, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss results from clinical trial studies using chemotherapy in combination with targeted agents for the treatment of early-stage breast cancer
Describe optimal treatment regimens for treating early-stage breast cancer patients
Recall the safety profiles associated with the use of targeted agents

CME CREDIT INFORMATION

Release Date: 02/27/07

Expiration Date: 02/26/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing CE credit

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.